The Tetracycline enabled self-silencing adenovirus (TESSA™) technology delivers a step-change in AAV manufacture; where AAV particles are produced free of traditional helper plasmid systems. Recent improvements in the technology have strengthened the platform’s versatility, enabling improved accessibility to a larger spectrum of AAV gene therapy scientists.